ATE252639T1 - Modifizierter, das dorsalgewebe beeinflussender faktor - Google Patents
Modifizierter, das dorsalgewebe beeinflussender faktorInfo
- Publication number
- ATE252639T1 ATE252639T1 AT98936850T AT98936850T ATE252639T1 AT E252639 T1 ATE252639 T1 AT E252639T1 AT 98936850 T AT98936850 T AT 98936850T AT 98936850 T AT98936850 T AT 98936850T AT E252639 T1 ATE252639 T1 AT E252639T1
- Authority
- AT
- Austria
- Prior art keywords
- factor affecting
- modified factor
- dorsal tissue
- muteins
- dorsal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/897,236 US6075007A (en) | 1997-07-17 | 1997-07-17 | Modified noggin polypeptide and compositions |
PCT/US1998/014603 WO1999003996A1 (en) | 1997-07-17 | 1998-07-17 | Modified dorsal tissue affecting factor and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE252639T1 true ATE252639T1 (de) | 2003-11-15 |
Family
ID=25407592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98936850T ATE252639T1 (de) | 1997-07-17 | 1998-07-17 | Modifizierter, das dorsalgewebe beeinflussender faktor |
Country Status (10)
Country | Link |
---|---|
US (3) | US6075007A (de) |
EP (1) | EP1003860B1 (de) |
JP (1) | JP4181300B2 (de) |
AT (1) | ATE252639T1 (de) |
AU (1) | AU735851B2 (de) |
CA (1) | CA2296769C (de) |
DE (1) | DE69819167T2 (de) |
HK (1) | HK1026229A1 (de) |
IL (2) | IL134042A0 (de) |
WO (1) | WO1999003996A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5471299A (en) | 1998-08-20 | 2000-03-14 | Regeneron Pharmaceuticals, Inc. | Dcr5, a bmp-binding protein, and applications thereof |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
DK1721979T3 (da) | 1998-11-27 | 2010-12-13 | Ucb Pharma Sa | Sammensætninger og fremgangsmåder til forøgelse af knoglemineralisering |
US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
AU2002243495A1 (en) * | 2001-01-12 | 2002-07-24 | University Of Medicine And Dentistry Of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
US20020197648A1 (en) * | 2001-05-02 | 2002-12-26 | Silva Robin M. | High throughput screening methods using magnetic resonance imaging agents |
US20030134790A1 (en) * | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
AU2003215297A1 (en) * | 2002-02-15 | 2003-09-09 | Cornell Research Foundation, Inc. | Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein |
AU2003221841A1 (en) | 2002-04-03 | 2003-10-27 | Celltech R And D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
ATE540977T1 (de) * | 2003-03-14 | 2012-01-15 | Ucb Mfg Inc | Komplex von sclerostin mit noggin oder chordin, und modulatoren der bildung dieses komplexes |
BRPI0411552A (pt) | 2003-06-16 | 2006-08-01 | Celltech R & D Inc | anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea |
DK2341147T3 (da) * | 2004-07-09 | 2019-11-11 | Viacyte Inc | Præprimitive stribe- og mesendodermceller |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
AU2006289667A1 (en) * | 2005-09-08 | 2007-03-15 | Apollo Life Sciences Limited | Noggin and chimeric molecules thereof |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
KR101163171B1 (ko) * | 2009-01-20 | 2012-07-19 | (주)케어젠 | 노긴?유래 펩타이드 및 그의 용도 |
US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
US20100272695A1 (en) * | 2009-04-22 | 2010-10-28 | Alan Agulnick | Cell compositions derived from dedifferentiated reprogrammed cells |
MX2012013268A (es) | 2010-05-14 | 2013-05-28 | Amgen Inc | Formulaciones de anticuerpos de alta concentracion. |
US20140080153A1 (en) * | 2011-01-07 | 2014-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
KR20140018315A (ko) | 2011-03-25 | 2014-02-12 | 암젠 인크 | 항스클러로스틴 항체 결정 및 이의 제제 |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
LT2739311T (lt) | 2011-08-04 | 2018-06-11 | Amgen Inc. | Kaulų tarpų defektų gydymo būdas |
BR112014016108A2 (pt) | 2011-12-28 | 2018-09-11 | Amgen Inc | método de tratamento de perda óssea alvelar |
AU2013285488B2 (en) | 2012-07-05 | 2018-03-22 | Ucb Pharma S.A. | Treatment for bone diseases |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
MA40354A (fr) | 2014-07-18 | 2017-05-24 | Sanofi Sa | Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
EP3534947A1 (de) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren |
EP3774879A1 (de) | 2018-03-30 | 2021-02-17 | Amgen Inc. | C-terminale antikörpervarianten |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256568A (en) | 1990-02-12 | 1993-10-26 | Regeneron Phamaceuticals, Inc. | Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers |
DK0550665T3 (da) | 1990-09-25 | 1996-12-02 | Genentech Inc | Ny neurotrofisk faktor |
ZA936478B (en) * | 1992-09-03 | 1994-09-30 | Regeneron Pharma | Dorsal tissue affecting factor and compositions |
EP0656062B1 (de) * | 1992-09-03 | 2000-03-08 | Regeneron Pharmaceuticals, Inc. | Dorsalgewebe beeinflussender faktor und zusammensetzungen |
-
1997
- 1997-07-17 US US08/897,236 patent/US6075007A/en not_active Expired - Fee Related
-
1998
- 1998-07-17 DE DE69819167T patent/DE69819167T2/de not_active Expired - Lifetime
- 1998-07-17 CA CA002296769A patent/CA2296769C/en not_active Expired - Fee Related
- 1998-07-17 AU AU85708/98A patent/AU735851B2/en not_active Ceased
- 1998-07-17 WO PCT/US1998/014603 patent/WO1999003996A1/en active IP Right Grant
- 1998-07-17 AT AT98936850T patent/ATE252639T1/de not_active IP Right Cessation
- 1998-07-17 IL IL13404298A patent/IL134042A0/xx active IP Right Grant
- 1998-07-17 JP JP2000503202A patent/JP4181300B2/ja not_active Expired - Fee Related
- 1998-07-17 EP EP98936850A patent/EP1003860B1/de not_active Expired - Lifetime
-
2000
- 2000-01-13 IL IL134042A patent/IL134042A/en not_active IP Right Cessation
- 2000-02-08 US US09/500,253 patent/US6500640B1/en not_active Expired - Fee Related
- 2000-08-24 HK HK00105325A patent/HK1026229A1/xx not_active IP Right Cessation
-
2002
- 2002-12-19 US US10/323,268 patent/US20030129703A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1026229A1 (en) | 2000-12-08 |
AU8570898A (en) | 1999-02-10 |
EP1003860A1 (de) | 2000-05-31 |
EP1003860B1 (de) | 2003-10-22 |
WO1999003996A1 (en) | 1999-01-28 |
IL134042A (en) | 2006-12-10 |
IL134042A0 (en) | 2001-04-30 |
CA2296769A1 (en) | 1999-01-28 |
AU735851B2 (en) | 2001-07-19 |
CA2296769C (en) | 2008-01-15 |
DE69819167D1 (de) | 2003-11-27 |
JP4181300B2 (ja) | 2008-11-12 |
US20030129703A1 (en) | 2003-07-10 |
DE69819167T2 (de) | 2004-07-22 |
US6075007A (en) | 2000-06-13 |
JP2001510044A (ja) | 2001-07-31 |
US6500640B1 (en) | 2002-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE252639T1 (de) | Modifizierter, das dorsalgewebe beeinflussender faktor | |
DE69403642D1 (de) | 7-deazapurin modifizierte oligonukleotide | |
ID26326A (id) | Deripat-deripat 2 purin 9 il tetrahiderofuran 3,4 diol | |
BR9916896A (pt) | Diaril aminas substituìdas com 1-heterociclo | |
PT1091975E (pt) | Nova ciclosporina com um perfil de actividade melhorado | |
HK1008347A1 (en) | Dorsal tissue affecting factor and compositions | |
WO1999051731A3 (en) | Maize histone deacetylases and their use | |
DK1123414T3 (da) | Antisense-modulering af integrin alpha 4.ekspression | |
NO986034D0 (no) | Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse | |
IT1293691B1 (it) | Stent per angioplastica, particolarmente per il trattamento di vasi presentanti biforcazioni. | |
NO20013102L (no) | Gener, proteiner og deres anvendelse | |
DE50009838D1 (de) | Humanes antibiotisches protein | |
PE20399A1 (es) | Muteina ob | |
HK1039339A1 (en) | Outer surface proteins, their genes, and their use. | |
DE10081621D2 (de) | Promotorsystem, dessen Herstellung und Verwendung | |
DE69828906D1 (de) | Herstellung von 1,3 propandiolestern | |
IT242987Y1 (it) | Guarnitura per mobili. | |
DE69823022D1 (de) | Neues, menschliches tumorsuppressorgen. | |
ITBO970602A0 (it) | Apparecchiatura per trattamento di dialisi. | |
NO179773C (no) | Fjernbar, ortopedisk brudd-stabilisator | |
AP2005003413A0 (en) | Genes and proteins, and their use. | |
CA2143442A1 (en) | Dorsal tissue affecting factor and compositions | |
ITFO980026U1 (it) | Perfezionamenti nelle basi per ponteggi mobili. | |
SE9704723D0 (sv) | Ligands | |
ES1034050Y (es) | Un clavo de implantacion en fracturas oseas, mejorado. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1003860 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |